RA Capital fund trims Vor Biopharma (VOR) stake with 630K-share sale

Rhea-AI Filing Summary

Vor Biopharma Inc. reported that an investment vehicle associated with RA Capital executed open-market sales of its Common Stock. On April 17, 2026, the RA Capital Healthcare Fund LP sold 458,411 shares at a weighted average price of $16.28 per share, in multiple trades between $15.95 and $16.85.

On April 20, 2026, the Fund sold an additional 171,963 shares at a weighted average price of $15.77 per share, with individual trades between $15.75 and $16.00. Following these transactions, the Fund held 2,567,245 shares of Vor Biopharma common stock indirectly, and RA Capital Management, its general partner and principals disclaim beneficial ownership beyond their pecuniary interests.

Insider Trade Summary

Net Seller: 630,374 shares ($10,174,788)

Net Sell 2 txns

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.

Role null | null | null | null

Sold 630,374 shs ($10.17M)

Type	Security	Shares	Price	Value
Sale	Common Stock	171,963	$15.77	$2.71M
Sale	Common Stock	458,411	$16.28	$7.46M

Holdings After Transaction: Common Stock — 2,567,245 shares (Indirect, See footnotes)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $16.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold Apr 17, 2026: 458,411 shares Weighted avg price Apr 17, 2026: $16.28/share Price range Apr 17, 2026: $15.95–$16.85 +5 more

8 metrics

Shares sold Apr 17, 2026 458,411 shares Open-market sale of Common Stock at weighted average price

Weighted avg price Apr 17, 2026 $16.28/share Vor Biopharma Common Stock sale by RA Capital fund

Price range Apr 17, 2026 $15.95–$16.85 Range of individual trade prices for that day’s sale

Shares sold Apr 20, 2026 171,963 shares Second open-market sale of Common Stock

Weighted avg price Apr 20, 2026 $15.77/share Vor Biopharma Common Stock sale by RA Capital fund

Price range Apr 20, 2026 $15.75–$16.00 Range of individual trade prices for second sale

Total shares sold 630,374 shares Combined April 17 and April 20, 2026 transactions

Shares held after transactions 2,567,245 shares Indirect Vor Biopharma holdings after April 20, 2026

Key Terms

weighted average price, beneficial ownership, pecuniary interest, indirect, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"disclaims beneficial ownership of any of the reported securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of its or his respective pecuniary interest therein"

indirect financial

"total_shares_following_transaction ... ownership_type: "indirect""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		S		458,411	D	$16.28(1)	2,739,208	I	See footnotes(2)(3)
Common Stock	04/20/2026		S		171,963	D	$15.77(4)	2,567,245	I	See footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $16.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

3. Held directly by the Fund.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	04/21/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	04/21/2026
	/s/ Peter Kolchinsky, individually	04/21/2026
	/s/ Rajeev Shah, individually	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did RA Capital report in Vor Biopharma (VOR) shares?

RA Capital’s affiliated fund reported two open-market sales of Vor Biopharma Common Stock, totaling 630,374 shares. These trades occurred on April 17, 2026 and April 20, 2026 at weighted average prices around the mid‑$15 to $16 range.

How many Vor Biopharma (VOR) shares did RA Capital’s fund sell on April 17, 2026?

On April 17, 2026, RA Capital Healthcare Fund LP sold 458,411 shares of Vor Biopharma Common Stock. The weighted average sale price was $16.28 per share, with individual trades executed between $15.95 and $16.85 according to the Form 4 footnotes.

What was the size and pricing of RA Capital’s April 20, 2026 Vor Biopharma (VOR) sale?

On April 20, 2026, the affiliated RA Capital fund sold 171,963 Vor Biopharma shares. The weighted average price was $15.77 per share, with individual trades completed in a range from $15.75 to $16.00, as disclosed in the Form 4 footnotes.

How many Vor Biopharma (VOR) shares did RA Capital’s fund hold after these sales?

After completing the April 20, 2026 transaction, RA Capital Healthcare Fund LP held 2,567,245 shares of Vor Biopharma Common Stock indirectly. This post‑transaction figure reflects the remaining position reported in the Form 4’s ownership column for the non‑derivative holdings.

Who is considered the seller in the Vor Biopharma (VOR) Form 4 filed by RA Capital?

The Form 4 attributes the Vor Biopharma share sales to RA Capital Healthcare Fund LP. RA Capital Management, L.P., its general partner entity and principals are reporting persons but each disclaims beneficial ownership of the securities beyond their respective pecuniary interests.

Were RA Capital’s Vor Biopharma (VOR) trades single-price or multiple-price transactions?

Both reported Vor Biopharma sales used weighted average prices, indicating multiple trades at different prices. Footnotes state the April 17 trades ranged from $15.95–$16.85 and the April 20 trades ranged from $15.75–$16.00, with detailed price breakdowns available upon request.